Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Phase 3

Completed

Conditions: Venous Thrombosis

Interventions: Drug: Enoxaparin
Drug: Placebo for enoxaparin
Drug: Placebo for warfarin
Drug: warfarin
Drug: Placebo for apixaban
Drug: apixaban

First Posted Date: 2008-03-26

Last Posted Date: 2014-04-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5614

Registration Number: NCT00643201

Locations: 🇺🇸
Pasadena Center For Medical Research, St. Petersburg, Florida, United States
🇺🇸
Great Falls Clinic, Llp, Great Falls, Montana, United States
🇺🇸
Infectious Disease Of Indiana Psc, Carmel, Indiana, United States

and more 71 locations

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: TAK-442
Drug: Enoxaparin

First Posted Date: 2008-03-24

Last Posted Date: 2016-04-13

Lead Sponsor: Takeda

Target Recruit Count: 1045

Registration Number: NCT00641732

Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer

Phase 2

Terminated

Conditions: Central Venous Catheters
Catheter-related Occlusion
Deep Vein Thrombosis
Childhood Cancer
Catheter-related Infection

Interventions: Drug: Enoxaparin

First Posted Date: 2008-03-11

Last Posted Date: 2020-10-08

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 136

Registration Number: NCT00633061

Locations: 🇺🇸
Children's Medical Center, Dallas, Texas, United States

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Drug: enoxaparin
Procedure: primary PCI
Procedure: catheterisation
Drug: tenecteplase
Drug: clopidogrel

First Posted Date: 2008-02-26

Last Posted Date: 2019-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1899

Registration Number: NCT00623623

Locations: 🇮🇹
1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy
🇫🇷
1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
🇫🇷
1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France

and more 197 locations

Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin

Phase 4

Completed

Conditions: Acute Illness

Interventions: Drug: Enoxaparin
Drug: Placebo

First Posted Date: 2008-02-25

Last Posted Date: 2010-12-28

Lead Sponsor: Sanofi

Target Recruit Count: 8329

Registration Number: NCT00622648

Locations: 🇹🇳
Sanofi-Aventis Administrative Office, Megrine, Tunisia

Etude (Study) Phase I Enox - UnFractionated Heparin (UFH)

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: Enoxaparin

First Posted Date: 2008-02-22

Last Posted Date: 2011-03-15

Lead Sponsor: Sanofi

Target Recruit Count: 72

Registration Number: NCT00622115

Locations: 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Enoxaparin
Drug: Enoxaparin placebo
Drug: Rivaroxaban placebo

First Posted Date: 2007-12-12

Last Posted Date: 2016-09-15

Lead Sponsor: Bayer

Target Recruit Count: 8101

Registration Number: NCT00571649

Locations: 🇦🇷
Sanatorio Mitre, Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
🇨🇦
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
🇨🇦
Hotel Dieu-Grace Hospital, Windsor, Ontario, Canada

and more 10 locations

Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL)

Phase 4

Terminated

Conditions: Unstable Angina

Interventions: Drug: enoxaparin

First Posted Date: 2007-08-20

Last Posted Date: 2016-01-27

Lead Sponsor: Canadian Heart Research Centre

Target Recruit Count: 11

Registration Number: NCT00518245

Locations: 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada

Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients

Phase 3

Terminated

Conditions: Venous Thromboembolism

Interventions: Drug: Fondaparinux
Drug: Enoxaparin

First Posted Date: 2007-06-28

Last Posted Date: 2022-04-11

Lead Sponsor: Eastern Virginia Medical School

Target Recruit Count: 27

Registration Number: NCT00493896

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Phase 3

Completed

Conditions: Venous Thrombosis
Pulmonary Embolism

Interventions: Drug: Apixaban
Drug: Enoxaparin

First Posted Date: 2007-04-05

Last Posted Date: 2015-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6758

Registration Number: NCT00457002

Locations: 🇺🇸
Pulmonary & Critical Care Of Atlanta, Atlanta, Georgia, United States
🇺🇸
Atlanta Institute For Medical Research, Inc, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States

and more 45 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy